Outpatient Emergencies: Anaphylaxis

Medical Clinics of North America

Volumn 101, Issue 3, 2017, Pages 521-536

  Commins, Scott P ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Allergy; Anaphylaxis; IgE; Mast cell; Tryptase

Indexed keywords

CORTICOSTEROID; EPINEPHRINE; GLUCAGON; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYPERTENSIVE FACTOR; INFUSION FLUID; OXYGEN; SALBUTAMOL; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOCORTICOID; IMMUNOGLOBULIN E;

ANAPHYLAXIS; CLINICAL OBSERVATION; EMERGENCY CARE; EMERGENCY HEALTH SERVICE; ENDOTRACHEAL TUBE; EPINEPHRINE AUTOINJECTOR; EXTERNAL DEFIBRILLATOR; FOLLOW UP; HUMAN; INFUSION PUMP; MANUAL EMERGENCY VENTILATOR; OUTPATIENT CARE; OXYGEN SUPPLY; PATIENT EDUCATION; PATIENT POSITIONING; RESUSCITATION; REVIEW; EMERGENCY; HEMODYNAMICS; IMMUNOLOGY; OUTPATIENT; PATHOPHYSIOLOGY; PROCEDURES; RESPIRATION CONTROL; SEVERITY OF ILLNESS INDEX;

ADRENERGIC BETA-AGONISTS; AIRWAY MANAGEMENT; ANAPHYLAXIS; CARDIOPULMONARY RESUSCITATION; EMERGENCIES; EPINEPHRINE; GLUCOCORTICOIDS; HEMODYNAMICS; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOGLOBULIN E; OUTPATIENTS; SEVERITY OF ILLNESS INDEX;

EID: 85014115957     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2016.12.003     Document Type: Review

References (56)

1. 1 Neugut, A.I., Ghatak, A.T., Miller, R.L., Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med 161:1 (2001), 15–21.
2. 2 Wood, R.A., Camargo, C.A. Jr., Lieberman, P., et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol 133:2 (2014), 461–467.
3. 3 Brown, S.G., Stone, S.F., Fatovich, D.M., et al. Anaphylaxis: clinical patterns, mediator release, and severity. J Allergy Clin Immunol 132:5 (2013), 1141–1149.e5.
4. 4 Lieberman, P., Nicklas, R.A., Randolph, C., et al. Anaphylaxis–a practice parameter update 2015. Ann Allergy Asthma Immunol 115:5 (2015), 341–384.
5. 5 Sampson, H.A., Munoz-Furlong, A., Campbell, R.L., et al. Second symposium on the definition and management of anaphylaxis: summary report–second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 47:4 (2006), 373–380.
6. 6 Schwartz, L.B., Metcalfe, D.D., Miller, J.S., et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 316:26 (1987), 1622–1626.
7. 7 Vadas, P., Gold, M., Perelman, B., et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 358:1 (2008), 28–35.
8. 8 Ellis, A.K., Day, J.H., The role of epinephrine in the treatment of anaphylaxis. Curr Allergy Asthma Rep 3:1 (2003), 11–14.
9. 9 Ellis, A.K., Priority role of epinephrine in anaphylaxis further underscored–the impact on biphasic anaphylaxis. Ann Allergy Asthma Immunol, 115(3), 2015, 165.
10. 10 Ellis, A.K., Day, J.H., Incidence and characteristics of biphasic anaphylaxis: a prospective evaluation of 103 patients. Ann Allergy Asthma Immunol 98:1 (2007), 64–69.
11. 11 Altman, A.M., Camargo, C.A., Simons, F.E., et al. Anaphylaxis in America: a national physician survey. J Allergy Clin Immunol 135:3 (2015), 830–833.
12. 12 Lieberman, P., Nicklas, R.A., Oppenheimer, J., et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 126:3 (2010), 477–480.e1-42.
13. 13 Viner, N.A., Rhamy, R.K., Anaphylaxis manifested by hypotension alone. J Urol 113:1 (1975), 108–110.
14. 14 Sampson, H.A., Munoz-Furlong, A., Bock, S.A., et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 115:3 (2005), 584–591.
15. 15 Valabhji, J., Robinson, S., Johnston, D., et al. Unexplained loss of consciousness: systemic mastocytosis. J R Soc Med 93:3 (2000), 141–142.
16. 16 Commins, S.P., Satinover, S.M., Hosen, J., et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol 123:2 (2009), 426–433.
17. 17 Chung, C.H., Mirakhur, B., Chan, E., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358:11 (2008), 1109–1117.
18. 18 Commins, S.P., James, H.R., Kelly, L.A., et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose. J Allergy Clin Immunol 127:5 (2011), 1286–1293.e6.
19. 19 Campbell, R.L., Li, J.T., Nicklas, R.A., et al. Members of the Joint Task Force, Practice Parameter Workgroup. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. Ann Allergy Asthma Immunol 113:6 (2014), 599–608.
20. 20 Ellis, A.K., Day, J.H., Diagnosis and management of anaphylaxis. CMAJ 169:4 (2003), 307–311.
21. 21 Toogood, J.H., Risk of anaphylaxis in patients receiving beta-blocker drugs. J Allergy Clin Immunol 81:1 (1988), 1–5.
22. 22 Berg, R.A., Hemphill, R., Abella, B.S., et al. Part 5: adult basic life support: 2010 American Heart association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 122:18 Suppl 3 (2010), S685–S705.
23. 23 Commins, S.P., Platts-Mills, T.A., Allergenicity of carbohydrates and their role in anaphylactic events. Curr Allergy Asthma Rep 10:1 (2010), 29–33.
24. 24 Kaliner, M., Shelhamer, J.H., Ottesen, E.A., Effects of infused histamine: correlation of plasma histamine levels and symptoms. J Allergy Clin Immunol 69:3 (1982), 283–289.
25. 25 Maier, S., Chung, C.H., Morse, M., et al. A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions. Cancer Med 4:1 (2014), 36–42.
26. 26 Pointreau, Y., Commins, S.P., Calais, G., et al. Fatal infusion reactions to cetuximab: role of immunoglobulin e-mediated anaphylaxis. J Clin Oncol, 30(3), 2012, 334 [author reply: 335].
27. 27 Simon, R.A., Schatz, M., Stevenson, D.D., et al. Radiographic contrast media infusions. Measurement of histamine, complement, and fibrin split products and correlation with clinical parameters. J Allergy Clin Immunol 63:4 (1979), 281–288.
28. 28 Bock, S.A., Munoz-Furlong, A., Sampson, H.A., Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 119:4 (2007), 1016–1018.
29. 29 Bock, S.A., Munoz-Furlong, A., Sampson, H.A., Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 107:1 (2001), 191–193.
30. 30 Neumar, R.W., Otto, C.W., Link, M.S., et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 122:18 Suppl 3 (2010), S729–S767.
31. 31 Beavers, C.J., Pandya, K.A., Pharmacotherapy considerations for the management of advanced cardiac life support. Nurs Clin North Am 51:1 (2016), 69–82.
32. 32 Hannibal, G.B., 2015 advanced cardiac life support updates and strategies for improving survival after cardiac arrest. AACN Adv Crit Care 27:2 (2016), 241–247.
33. 33 Orban, J.C., Giolito, D., Tosi, J., et al. Factors associated with initiation of medical advanced cardiac life support after out-of-hospital cardiac arrest. Ann Intensive Care, 6(1), 2016, 12.
34. 34 Rank, M.A., Oslie, C.L., Krogman, J.L., et al. Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors. Allergy Asthma Proc 29:4 (2008), 400–405.
35. 35 Simons, F.E., Gu, X., Simons, K.J., Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol 108:5 (2001), 871–873.
36. 36 Simons, F.E., Roberts, J.R., Gu, X., et al. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol 101:1 Pt 1 (1998), 33–37.
37. 37 Manivannan, V., Campbell, R.L., Bellolio, M.F., et al. Factors associated with repeated use of epinephrine for the treatment of anaphylaxis. Ann Allergy Asthma Immunol 103:5 (2009), 395–400.
38. 38 Oren, E., Banerji, A., Clark, S., et al. Food-induced anaphylaxis and repeated epinephrine treatments. Ann Allergy Asthma Immunol 99:5 (2007), 429–432.
39. 39 Sampson, H.A., Mendelson, L., Rosen, J.P., Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 327:6 (1992), 380–384.
40. 40 Simons, F.E., Frew, A.J., Ansotegui, I.J., et al. Practical allergy (PRACTALL) report: risk assessment in anaphylaxis. Allergy 63:1 (2008), 35–37.
41. 41 Ali, J., Adam, R.U., Gana, T.J., et al. Trauma patient outcome after the Prehospital Trauma Life Support program. J Trauma 42:6 (1997), 1018–1021 [discussion: 1021–2].
42. 42 Wolfl, C.G., Bouillon, B., Lackner, C.K., et al. Prehospital Trauma Life Support (PHTLS): an interdisciplinary training in preclinical trauma care. Unfallchirurg 111:9 (2008), 688–694 [in German].
43. 43 Peberdy, M.A., Callaway, C.W., Neumar, R.W., et al. Part 9: post-cardiac arrest care: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 122:18 Suppl 3 (2010), S768–S786.
44. 44 Pumphrey, R.S., Fatal posture in anaphylactic shock. J Allergy Clin Immunol 112:2 (2003), 451–452.
45. 45 Berg, M.D., Schexnayder, S.M., Chameides, L., et al. Part 13: pediatric basic life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 122:18 Suppl 3 (2010), S862–S875.
46. 46 Brown, S.G., Blackman, K.E., Stenlake, V., et al. Insect sting anaphylaxis; prospective evaluation of treatment with intravenous adrenaline and volume resuscitation. Emerg Med J 21:2 (2004), 149–154.
47. 47 Toogood, J.H., Beta-blocker therapy and the risk of anaphylaxis. CMAJ 137:7 (1987), 587–588 590–1.
48. 48 Vander Zanden, J.A., Valuck, R.J., Bunch, C.L., et al. Systemic adverse effects of ophthalmic beta-blockers. Ann Pharmacother 35:12 (2001), 1633–1637.
49. 49 Matasar, M.J., Neugut, A.I., Epidemiology of anaphylaxis in the United States. Curr Allergy Asthma Rep 3:1 (2003), 30–35.
50. 50 Mulla, Z.D., Lin, R.Y., Simon, M.R., Perspectives on anaphylaxis epidemiology in the United States with new data and analyses. Curr Allergy Asthma Rep 11:1 (2011), 37–44.
51. 51 Commins, S.P., James, H.R., Stevens, W., et al. Delayed clinical and ex vivo response to mammalian meat in patients with IgE to galactose-alpha-1,3-galactose. J Allergy Clin Immunol 134:1 (2014), 108–115.
52. 52 Sicherer, S.H., Sampson, H.A., Food allergy: epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol 133:2 (2014), 291–307 [quiz: 308].
53. 53 Atkins, D., Bock, S.A., Fatal anaphylaxis to foods: epidemiology, recognition, and prevention. Curr Allergy Asthma Rep 9:3 (2009), 179–185.
54. 54 Yu, J.E., Lin, R.Y., The epidemiology of anaphylaxis. Clin Rev Allergy Immunol, 2015.
55. 55 Boyce, J.A., Assa'ad, A., Burks, A.W., et al. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report. Nutr Res 31:1 (2011), 61–75.
56. 56 Simons, F.E., Frew, A.J., Ansotegui, I.J., et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 120:1 Suppl (2007), S2–S24.